WILL THE MRNA FLU SHOT WORK BETTER THAN A REGULAR SEASONAL ONE? WHAT THE SCIENCE SAYS

Moderna’s newly approved mRNA influenza vaccine has been cleared for use in the United States, prompting questions about whether it will outperform traditional seasonal flu shots. The approval, announced by the Food and Drug Administration on 13 August 2026, was reported by Nature in an online article that discusses the scientific evidence surrounding the new vaccine.

The Nature article notes that the mRNA platform—long used for COVID‑19 vaccines—could allow manufacturers to adapt more quickly to emerging influenza strains. While the piece does not provide specific efficacy data, it highlights the potential for more rapid vaccine updates and production scalability compared with conventional egg‑based or cell‑culture methods.

The mRNA technology has already demonstrated superior flexibility and speed in pandemic responses, and its application to influenza could reshape annual vaccination strategies worldwide.

• Moderna’s mRNA flu vaccine received FDA approval on 13 August 2026.
• Nature reports that the platform could enable faster response to changing influenza strains.
• No detailed efficacy numbers are provided in the article, but the potential for quicker vaccine updates is emphasized.

Read the original source for full detail available at Nature src